About Mesoblast
Mesoblast is a company based in Melbourne (Australia) founded in 2004.. The company has 81 employees as of June 30, 2025. Mesoblast has completed 2 acquisitions, including Angioblast Systems and Provasculon. Mesoblast operates in a competitive market with competitors including RoosterBio, SanBio, Cellular Biomedicine Group, BrainStorm Cell and SCM Lifescience, among others.
- Headquarter Melbourne, Australia
- Employees 81 as on 30 Jun, 2025
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mesoblast Limited
-
Annual Revenue
$17.55 M (USD)194.84as on Jun 30, 2025
-
Net Profit
$-104.22 M (USD)-17.5as on Jun 30, 2025
-
EBITDA
$-57.27 M (USD)-4.85as on Jun 30, 2025
-
Latest Funding Round
$159.98 M (USD), Post-IPO
Jan 14, 2025
-
Investors
Hercules Capital
& 5 more
-
Employee Count
81
as on Jun 30, 2025
-
Investments & Acquisitions
Angioblast Systems
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mesoblast
Mesoblast is a publicly listed company on the ASX with ticker symbol MSB in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Software Development Team
9 people
Leadership Team
7 people
Finance and Accounting
5 people
Operations Team
4 people
Product Management Team
4 people
Principal Team
2 people
Senior Team
2 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Mesoblast
- Total Funding Total Funding
- Total Rounds 16
- Last Round Post-IPO — $160.0M
-
First Round
First Round
(01 Jun 2005)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Post-IPO - Mesoblast | Valuation |
investors |
|
| Apr, 2023 | Amount | Post-IPO - Mesoblast | Valuation |
investors |
|
| Aug, 2022 | Amount | Post-IPO - Mesoblast | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mesoblast
Mesoblast has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, M&G and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified asset management firm and private fund focused on debt and equity investments in climate startups, real estate, and multiple sectors
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Provider of public, living relief, strengthening medicare, jobs, skills and training services
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mesoblast
Mesoblast has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Angioblast Systems and Provasculon. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
New blood vessel growth is stimulated through SDF-1 regenerative solutions.
|
2007 | ||||
|
Therapeutic products for cardiovascular diseases are developed and commercialized.
|
2001 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Mesoblast
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mesoblast Comparisons
Competitors of Mesoblast
Mesoblast operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RoosterBio, SanBio, Cellular Biomedicine Group, BrainStorm Cell and SCM Lifescience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| domain | founded_year | HQ Location |
Regenerative cell medicines for neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapeutics are developed for cancer, orthopaedics, and COPD.
|
|
| domain | founded_year | HQ Location |
Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD
|
|
| domain | founded_year | HQ Location |
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mesoblast
Frequently Asked Questions about Mesoblast
When was Mesoblast founded?
Mesoblast was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Mesoblast located?
Mesoblast is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
How many employees does Mesoblast have?
As of Jun 30, 2025, the latest employee count at Mesoblast is 81.
What is the annual revenue of Mesoblast?
Annual revenue of Mesoblast is $17.55M as on Jun 30, 2025.
What does Mesoblast do?
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low back pain due to degenerative disc disease.
Who are the top competitors of Mesoblast?
Mesoblast's top competitors include RoosterBio, SanBio and BrainStorm Cell.
Is Mesoblast publicly traded?
Yes, Mesoblast is publicly traded on ASX under the ticker symbol MSB.
How many acquisitions has Mesoblast made?
Mesoblast has made 2 acquisitions, including Angioblast Systems, and Provasculon.
Who are Mesoblast's investors?
Mesoblast has 6 investors. Key investors include Hercules Capital, M&G, Celgene, Cephalon, and Government of Australia.
What is Mesoblast's ticker symbol?
The ticker symbol of Mesoblast is MSB on ASX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.